Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions
PCVX Stock Forecast
Vaxcyte stock forecast is as follows: an average price target of $124.14 (represents a 7.02% upside from PCVX’s last price of $116.00) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
PCVX Price Target
The average price target for Vaxcyte (PCVX) is $124.14 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $163.00 to $58.00. This represents a potential 7.02% upside from PCVX's last price of $116.00.
PCVX Analyst Ratings
According to 8 Wall Street analysts, Vaxcyte's rating consensus is 'Buy'. The analyst rating breakdown for PCVX stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vaxcyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Salim Syed | Mizuho Securities | $163.00 | $115.28 | 41.39% | 40.52% |
| Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $140.00 | $110.15 | 27.10% | 20.69% |
| Sep 03, 2024 | David Risinger | Leerink Partners | $153.00 | $112.04 | 36.56% | 31.90% |
| Sep 03, 2024 | Tom Shrader | BTIG | $160.00 | $110.15 | 45.26% | 37.93% |
| Sep 03, 2024 | Roger Song | Jefferies | $129.00 | $111.13 | 16.09% | 11.21% |
| Sep 03, 2024 | Salim Syed | Mizuho Securities | $113.00 | $111.08 | 1.72% | -2.59% |
| Aug 07, 2024 | Tom Shrader | BTIG | $98.00 | $70.52 | 38.97% | -15.52% |
| Jan 03, 2023 | - | Needham | $58.00 | $47.95 | 20.96% | -50.00% |
| Dec 16, 2022 | - | Leerink Partners | $60.00 | $45.48 | 31.93% | -48.28% |
| Dec 15, 2022 | - | Guggenheim | $66.00 | $45.72 | 44.36% | -43.10% |
The latest Vaxcyte stock forecast, released on Sep 10, 2024 by Salim Syed from Mizuho Securities, set a price target of $163.00, which represents a 41.39% increase from the stock price at the time of the forecast ($115.28), and a 40.52% increase from PCVX last price ($116.00).
Vaxcyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 6 | 7 | 7 |
| Avg Price Target | $143.00 | $136.57 | $136.57 |
| Last Closing Price | $116.00 | $116.00 | $116.00 |
| Upside/Downside | 23.28% | 17.73% | 17.73% |
In the current month, the average price target of Vaxcyte stock is $143.00, according to 6 Wall Street analysts offering twelve months forecast. The average price target represents a 23.28% increase as opposed to Vaxcyte's last price of $116.00. This month's average price target is up 4.71% compared to last quarter, and up 4.71% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 03, 2024 | Needham | Buy | Buy | Hold |
| Sep 03, 2024 | BTIG | Buy | Buy | Hold |
| Sep 03, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 07, 2024 | BTIG | Buy | Buy | Hold |
| Mar 12, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Mar 12, 2024 | Wedbush | Buy | Buy | Hold |
| Jan 03, 2023 | Needham | Buy | Buy | Hold |
| Dec 16, 2022 | SVB Leerink | - | Outperform | Initialise |
Vaxcyte's last stock rating was published by Guggenheim on Sep 04, 2024. The company gave PCVX a "Buy" rating, the same as its previous rate.
Vaxcyte Financial Forecast
Vaxcyte Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $166.67K |
| High Forecast | - | - | - | - | - | - | - | $166.67K |
| Low Forecast | - | - | - | - | - | - | - | $166.67K |
| # Analysts | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Vaxcyte's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PCVX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vaxcyte EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $-19.96M |
| Avg Forecast | - | - | - | - | - | - | - | $-12.81M |
| High Forecast | - | - | - | - | - | - | - | $-10.24M |
| Low Forecast | - | - | - | - | - | - | - | $-15.37M |
| Surprise % | - | - | - | - | - | - | - | 1.56% |
undefined analysts predict PCVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vaxcyte's previous annual EBITDA (undefined) of $NaN.
Vaxcyte Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | $-20.32M |
| Avg Forecast | $-164.16M | $-158.30M | $-158.30M | $-152.43M | $-141.69M | $-131.52M | $-114.39M | $-13.12M |
| High Forecast | $-164.16M | $-158.30M | $-158.30M | $-152.43M | $-141.69M | $-118.10M | $-114.39M | $-10.50M |
| Low Forecast | $-164.16M | $-158.30M | $-158.30M | $-152.43M | $-141.69M | $-146.28M | $-114.39M | $-15.74M |
| Surprise % | - | - | - | - | - | - | - | 1.55% |
Vaxcyte's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PCVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vaxcyte SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | $2.01M |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Vaxcyte's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PCVX last annual SG&A of $2.01M (Jun 20).
Vaxcyte EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | $-1.72 |
| Avg Forecast | $-1.40 | $-1.35 | $-1.35 | $-1.30 | $-1.21 | $-1.12 | $-0.98 | $-1.27 |
| High Forecast | $-1.40 | $-1.35 | $-1.35 | $-1.30 | $-1.21 | $-1.01 | $-0.98 | $-1.27 |
| Low Forecast | $-1.40 | $-1.35 | $-1.35 | $-1.30 | $-1.21 | $-1.25 | $-0.98 | $-1.27 |
| Surprise % | - | - | - | - | - | - | - | 1.36% |
According to undefined Wall Street analysts, Vaxcyte's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PCVX previous annual EPS of $NaN (undefined).
Vaxcyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| STRO | Sutro Biopharma | $4.50 | $10.80 | 140.00% | Buy |
| IMCR | Immunocore | $33.55 | $75.50 | 125.04% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| LQDA | Liquidia | $9.80 | $17.17 | 75.20% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| TECH | Bio-Techne | $74.67 | $99.21 | 32.86% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
PCVX Forecast FAQ
Is Vaxcyte a good buy?
Yes, according to 8 Wall Street analysts, Vaxcyte (PCVX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of PCVX's total ratings.
What is PCVX's price target?
Vaxcyte (PCVX) average price target is $124.14 with a range of $58 to $163, implying a 7.02% from its last price of $116. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vaxcyte stock go up soon?
According to Wall Street analysts' prediction for PCVX stock, the company can go up by 7.02% (from the last price of $116 to the average price target of $124.14), up by 40.52% based on the highest stock price target, and down by -50.00% based on the lowest stock price target.
Can Vaxcyte stock reach $200?
PCVX's average twelve months analyst stock price target of $124.14 does not support the claim that Vaxcyte can reach $200 in the near future.
What is Vaxcyte's current price target trend?
6 Wall Street analysts forecast a $143 price target for Vaxcyte (PCVX) this month, up 23.28% from its last price of $116. Compared to the last 3 and 12 months, the average price target increased by 17.73% and increased by 17.73%, respectively.
What are Vaxcyte's analysts' financial forecasts?
Vaxcyte's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-388M (high $-374M, low $-402M), average SG&A $0 (high $0, low $0), and average EPS is $-3.306 (high $-3.191, low $-3.432). PCVX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-633M (high $-633M, low $-633M), average SG&A $0 (high $0, low $0), and average EPS is $-5.4 (high $-5.4, low $-5.4).